BACKGROUND: In multiple sclerosis (MS), the immune system acts against myelin lesions of the central nervous system, destroying neuronal fibers resulting in signal transmission disturbances in the nervous system. MicroRNAs play important roles in the post-transcriptional regulation of gene expression and in the regulation of disease activity and its response to treatment. The goal of this study was to determine the role of miR-18a-5p by comparing its expression in MS patients and healthy subjects. METHODS: RNA was isolated from blood samples of 32 MS patients and 32 healthy individuals, and miR-18a-5p expression was determined by real-time polymerase chain reaction (real-time PCR). RESULTS: miR-18a-5p expression was significantly less in MS patients than in healthy subjects. CONCLUSION: The reduction of miR-18a-5p expression may be via pathway signaling. Altered signaling plays an important role in MS pathogenesis and the miR-18a-5p expression profile in blood cells can be described as a prognostic biomarker and identifier of high-risk individuals in MS.
BACKGROUND: In multiple sclerosis (MS), the immune system acts against myelin lesions of the central nervous system, destroying neuronal fibers resulting in signal transmission disturbances in the nervous system. MicroRNAs play important roles in the post-transcriptional regulation of gene expression and in the regulation of disease activity and its response to treatment. The goal of this study was to determine the role of miR-18a-5p by comparing its expression in MS patients and healthy subjects. METHODS: RNA was isolated from blood samples of 32 MS patients and 32 healthy individuals, and miR-18a-5p expression was determined by real-time polymerase chain reaction (real-time PCR). RESULTS: miR-18a-5p expression was significantly less in MS patients than in healthy subjects. CONCLUSION: The reduction of miR-18a-5p expression may be via pathway signaling. Altered signaling plays an important role in MS pathogenesis and the miR-18a-5p expression profile in blood cells can be described as a prognostic biomarker and identifier of high-risk individuals in MS.
Authors: Misty M Montoya; Julia Maul; Priti B Singh; Heather H Pua; Frank Dahlström; Nanyan Wu; Xiaozhu Huang; K Mark Ansel; Dirk Baumjohann Journal: J Immunol Date: 2017-06-12 Impact factor: 5.422
Authors: Andreas Junker; Markus Krumbholz; Sylvia Eisele; Hema Mohan; Florian Augstein; Robert Bittner; Hans Lassmann; Hartmut Wekerle; Reinhard Hohlfeld; Edgar Meinl Journal: Brain Date: 2009-12 Impact factor: 13.501
Authors: Antony Rodriguez; Elena Vigorito; Simon Clare; Madhuri V Warren; Philippe Couttet; Dalya R Soond; Stijn van Dongen; Russell J Grocock; Partha P Das; Eric A Miska; David Vetrie; Klaus Okkenhaug; Anton J Enright; Gordon Dougan; Martin Turner; Allan Bradley Journal: Science Date: 2007-04-27 Impact factor: 47.728
Authors: Jens Ingwersen; Til Menge; Britta Wingerath; Derya Kaya; Jonas Graf; Tim Prozorovski; Andreas Keller; Christina Backes; Markus Beier; Matthias Scheffler; Thomas Dehmel; Bernd C Kieseier; Hans-Peter Hartung; Patrick Küry; Orhan Aktas Journal: Ann Clin Transl Neurol Date: 2014-12-05 Impact factor: 4.511
Authors: Enrique González-Madrid; Ma Andreina Rangel-Ramírez; María José Mendoza-León; Oscar Álvarez-Mardones; Pablo A González; Alexis M Kalergis; Ma Cecilia Opazo; Claudia A Riedel Journal: Int J Mol Sci Date: 2022-06-25 Impact factor: 6.208